Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514680 · ClinicalTrials.gov registry record · NA
Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 226
- Enrollment target
NCT03514680 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 226 participants.
The verdict
NCT03514680, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 226 participants
- Enrollment target
Study Summary
This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.
Interventions
- BEHAVIORAL CIPN Assessment and Management Algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2020-03-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03514680
The ClinicalTrials.gov registry entry for NCT03514680 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CIPN Assessment and Management Algorithm is the first listed.
NCT03514680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03514680 about?
NCT03514680 is a clinical study titled "Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy". This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.
What is the current status of trial NCT03514680?
This trial is currently completed. It is a NA study. The enrollment target is 226 participants. The study started on 2018-06-04. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT03514680?
The interventions under investigation include: CIPN Assessment and Management Algorithm (BEHAVIORAL).
Who is sponsoring clinical trial NCT03514680?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.